<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37816742</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>A human monoclonal antibody binds within the poliovirus receptor-binding site to neutralize all three serotypes.</ArticleTitle><Pagination><StartPage>6335</StartPage><MedlinePgn>6335</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">6335</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-023-41052-9</ELocationID><Abstract><AbstractText>Global eradication of poliovirus remains elusive, and it is critical to develop next generation vaccines and antivirals. In support of this goal, we map the epitope of human monoclonal antibody 9H2 which is able to neutralize the three serotypes of poliovirus. Using cryo-EM we solve the near-atomic structures of 9H2 fragments (Fab) bound to capsids of poliovirus serotypes 1, 2, and 3. The Fab-virus complexes show that Fab interacts with the same binding mode for each serotype and at the same angle of interaction relative to the capsid surface. For each of the Fab-virus complexes, we find that the binding site overlaps with the poliovirus receptor (PVR) binding site and maps across and into a depression in the capsid called the canyon. No conformational changes to the capsid are induced by Fab binding for any complex. Competition binding experiments between 9H2 and PVR reveal that 9H2 impedes receptor binding. Thus, 9H2 outcompetes the receptor to neutralize poliovirus. The ability to neutralize all three serotypes, coupled with the critical importance of the conserved receptor binding site make 9H2 an attractive antiviral candidate for future development.</AbstractText><CopyrightInformation>© 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Charnesky</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Molecular, Cellular, and Integrative Biosciences Program, The Pennsylvania State University, University Park, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faust</LastName><ForeName>Julia E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, The Pennsylvania State University, University Park, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hyunwook</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5428-8594</Identifier><AffiliationInfo><Affiliation>Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, The Pennsylvania State University, University Park, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puligedda</LastName><ForeName>Rama Devudu</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Lankenau Institute for Medical Research, Lankenau Medical Center, 100 East Lancaster Avenue, Wynnewood, PA, 19096, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goetschius</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0002-6052-7141</Identifier><AffiliationInfo><Affiliation>Molecular, Cellular, and Integrative Biosciences Program, The Pennsylvania State University, University Park, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DiNunno</LastName><ForeName>Nadia M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Molecular, Cellular, and Integrative Biosciences Program, The Pennsylvania State University, University Park, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thapa</LastName><ForeName>Vaskar</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, The Pennsylvania State University, University Park, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bator</LastName><ForeName>Carol M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Sung Hyun Joseph</ForeName><Initials>SHJ</Initials><AffiliationInfo><Affiliation>Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wahid</LastName><ForeName>Rahnuma</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Vaccine Innovation and Access, PATH, Seattle, WA, 98121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahmood</LastName><ForeName>Kutub</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Vaccine Innovation and Access, PATH, Seattle, WA, 98121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dessain</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Lankenau Institute for Medical Research, Lankenau Medical Center, 100 East Lancaster Avenue, Wynnewood, PA, 19096, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chumakov</LastName><ForeName>Konstantin M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Office of Vaccines Research and Review, Division of Viral Products, Laboratory of Method Development, FDA, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenfeld</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Office of Vaccines Research and Review, Division of Viral Products, Laboratory of Method Development, FDA, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hafenstein</LastName><ForeName>Susan L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Molecular, Cellular, and Integrative Biosciences Program, The Pennsylvania State University, University Park, PA, USA. shafenstein@psu.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, PA, USA. shafenstein@psu.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, The Pennsylvania State University, University Park, PA, USA. shafenstein@psu.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, The Pennsylvania State University College of Medicine, Hershey, PA, USA. shafenstein@psu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI107121</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD026822</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C066100">poliovirus receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065288" MajorTopicYN="N">Serogroup</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="Y">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>2</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>11</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>10</Day><Hour>23</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37816742</ArticleId><ArticleId IdType="pmc">PMC10564760</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-41052-9</ArticleId><ArticleId IdType="pii">10.1038/s41467-023-41052-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Landsteiner K. Ubertragung der Poliomyelitis acuta auf Affen. Z. Immunitatsforsch. 1909;2:377–390.</Citation></Reference><Reference><Citation>Henry R. Etymologia: poliomyelitis. Emerg. Infect. Dis. 2019;25:1611–1611.</Citation></Reference><Reference><Citation>Mark, A., Pallansch, M., Steven, O. &amp; Whitton, J. L. In Fields Virology. Vol. 1. 510 (Wolters Kluwer, 2013).</Citation></Reference><Reference><Citation>Tuma JN, et al. Surveillance to track progress toward polio eradication—worldwide, 2019–2020. MMWR Morb. Mortal. Wkly. Rep. 2021;70:667–673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9368747</ArticleId><ArticleId IdType="pubmed">33956779</ArticleId></ArticleIdList></Reference><Reference><Citation>Filman DJ, et al. Structural factors that control conformational transitions and serotype specificity in TYPE-3 poliovirus. Embo J. 1989;8:1567–1579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC400988</ArticleId><ArticleId IdType="pubmed">2548847</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC Global Health-Polio-Our Progress. https://www.cdc.gov/polio/progress/index.htm (CDC Global Health, 2022).</Citation></Reference><Reference><Citation>Cann AJ, et al. Reversion to neurovirulence of the live-attenuated sabin type-3 oral poliovirus vaccine. Nucleic Acids Res. 1984;12:7787–7792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC320200</ArticleId><ArticleId IdType="pubmed">6093054</ArticleId></ArticleIdList></Reference><Reference><Citation>Alleman MM, et al. Update on vaccine-derived poliovirus outbreaks—Worldwide, July 2019–February 2020. MMWR Morb. Mortal. Wkly. Rep. 2020;69:489–495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7188410</ArticleId><ArticleId IdType="pubmed">32324719</ArticleId></ArticleIdList></Reference><Reference><Citation>Polio (Poliomyelitis, Infantile Paralysis). https://www.health.ny.gov/diseases/communicable/polio/ (2022).</Citation></Reference><Reference><Citation>Duizer, E. et al. Wild poliovirus type 3 (WPV3)-shedding event following detection in environmental surveillance of poliovirus essential facilities, the Netherlands, November 2022 to January 2023. Eurosurveillance28, 2300049 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9896605</ArticleId><ArticleId IdType="pubmed">36729115</ArticleId></ArticleIdList></Reference><Reference><Citation>Polio Wastewater Surveillance. https://www.health.ny.gov/diseases/communicable/polio/wastewater.htm.</Citation></Reference><Reference><Citation>Hogle JM, Chow M, Filman DJ. 3-dimensional structure of poliovirus at 2.9 A resolution. Science. 1985;229:1358–1365.</Citation><ArticleIdList><ArticleId IdType="pubmed">2994218</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, et al. Interaction of the poliovirus receptor with poliovirus. Proc. Natl Acad. Sci. USA. 2000;97:79–84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26619</ArticleId><ArticleId IdType="pubmed">10618374</ArticleId></ArticleIdList></Reference><Reference><Citation>Belnap DM, et al. Three-dimensional structure of poliovirus receptor bound to poliovirus. Proc. Natl Acad. Sci. USA. 2000;97:73–78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26618</ArticleId><ArticleId IdType="pubmed">10618373</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss M, et al. Nectin-like interactions between poliovirus and its receptor trigger conformational changes associated with cell entry. J. Virol. 2015;89:4143–4157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4442392</ArticleId><ArticleId IdType="pubmed">25631086</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith TJ, et al. The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science. 1986;233:1286–1293.</Citation><ArticleIdList><ArticleId IdType="pubmed">3018924</ArticleId></ArticleIdList></Reference><Reference><Citation>Blondel B, Akacem O, Crainic R, Couillin P, Horodniceanu F. Detection by monoclonal-antibodies of an antigenic determinant critical for poliovirus neutralization present on vp1 and on heat-inactivated virions. Virology. 1983;126:707–710.</Citation><ArticleIdList><ArticleId IdType="pubmed">6190311</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor PD, et al. Location and primary structure of a major antigenic site for poliovirus neutralization. Nature. 1983;301:674–679.</Citation><ArticleIdList><ArticleId IdType="pubmed">6186919</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond DC, et al. Antigenic variation and resistance to neutralization in poliovirus type 1. Science. 1985;229:1090–1093.</Citation><ArticleIdList><ArticleId IdType="pubmed">2412292</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor PD, et al. Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type-3. J. Gen. Virol. 1985;66:1159–1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">2582084</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor PD, Ferguson M, Evans DMA, Almond JW, Icenogle JP. Antigenic structure of polioviruses of serotype-1, serotype-2 and serotype-3. J. Gen. Virol. 1986;67:1283–1291.</Citation><ArticleIdList><ArticleId IdType="pubmed">2425046</ArticleId></ArticleIdList></Reference><Reference><Citation>Page GS, et al. 3-dimensional structure of poliovirus serotype-1 neutralizing determinants. J. Virol. 1988;62:1781–1794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC253228</ArticleId><ArticleId IdType="pubmed">2451757</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiore L, et al. Poliovirus Sabin type 1 neutralization epitopes recognized immunoglobulin A monoclonal antibodies. J. Virol. 1997;71:6905–6912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC191973</ArticleId><ArticleId IdType="pubmed">9261417</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen ZC, et al. Cross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptor. Proc. Natl Acad. Sci. USA. 2013;110:20242–20247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3864303</ArticleId><ArticleId IdType="pubmed">24277851</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss M, Schotte L, Thys B, Filman DJ, Hogle JM. Five of five VHHs neutralizing poliovirus bind the receptor-binding site. J. Virol. 2016;90:3496–3505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4794687</ArticleId><ArticleId IdType="pubmed">26764003</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus-molecular-cloning, nucleotide-sequence, and expression of a new member of the immunoglobulin superfamily. Cell. 1989;56:855–865.</Citation><ArticleIdList><ArticleId IdType="pubmed">2538245</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuthill TJ, Bubeck D, Rowlands DJ, Hogle JM. Characterization of early steps in the poliovirus infection process: receptor-decorated liposomes induce conversion of the virus to membrane-anchored entry-intermediate particles. J. Virol. 2006;80:172–180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1317540</ArticleId><ArticleId IdType="pubmed">16352541</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss M, Levy HC, Bostina M, Filman DJ, Hogle JM. RNA transfer from poliovirus 135S particles across membranes is mediated by long umbilical connectors. J. Virol. 2013;87:3903–3914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624230</ArticleId><ArticleId IdType="pubmed">23365424</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, et al. The novel asymmetric entry intermediate of a picornavirus captured with nanodiscs. Sci. Adv. 2016;2:e1501929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4996645</ArticleId><ArticleId IdType="pubmed">27574701</ArticleId></ArticleIdList></Reference><Reference><Citation>Butan C, Filman DJ, Hogle JM. Cryo-electron microscopy reconstruction shows poliovirus 135S particles poised for membrane interaction and RNA release. J. Virol. 2014;88:1758–1770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3911577</ArticleId><ArticleId IdType="pubmed">24257617</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickl-Herk A, et al. Uncoating of common cold virus is preceded by RNA switching as determined by X-ray and cryo-EM analyses of the subviral A-particle. Proc. Natl Acad. Sci. USA. 2013;110:20063–20068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3864292</ArticleId><ArticleId IdType="pubmed">24277846</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren J, et al. Picornavirus uncoating intermediate captured in atomic detail. Nat. Commun. 2013;4:1929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3709478</ArticleId><ArticleId IdType="pubmed">23728514</ArticleId></ArticleIdList></Reference><Reference><Citation>Puligedda RD, et al. Characterization of human monoclonal antibodies that neutralize multiple poliovirus serotypes. Vaccine. 2017;35:5455–5462.</Citation><ArticleIdList><ArticleId IdType="pubmed">28343771</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetschius DJ, et al. High resolution cryo EM analysis of HPV16 identifies minor structural protein L2 and describes capsid flexibility. Sci. Rep. 2021;11:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7876116</ArticleId><ArticleId IdType="pubmed">33568731</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Garcia R, et al. DeepEMhancer: a deep learning solution for cryo-EM volume post-processing. Commun. Biol. 2021;4:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8282847</ArticleId><ArticleId IdType="pubmed">34267316</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller ST, Hogle JM, Filman DJ. Ab initio phasing of high-symmetry macromolecular complexes: successful phasing of authentic poliovirus data to 3.0 Å resolution. J. Mol. Biol. 2001;307:499–512.</Citation><ArticleIdList><ArticleId IdType="pubmed">11254378</ArticleId></ArticleIdList></Reference><Reference><Citation>Lentz KN, et al. Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH48973: comparison of the structural and biological properties of the three poliovirus serotypes. Structure. 1997;5:961–978.</Citation><ArticleIdList><ArticleId IdType="pubmed">9261087</ArticleId></ArticleIdList></Reference><Reference><Citation>Leem J, Dunbar J, Georges G, Shi JY, Deane CM. ABodyBuilder: automated antibody structure prediction with data-driven accuracy estimation. Mabs. 2016;8:1259–1268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5058620</ArticleId><ArticleId IdType="pubmed">27392298</ArticleId></ArticleIdList></Reference><Reference><Citation>Wien MW, Curry S, Filman DJ, Hogle JM. Structural studies of poliovirus mutants that overcome receptor defects. Nat. Struct. Biol. 1997;4:666–674.</Citation><ArticleIdList><ArticleId IdType="pubmed">9253417</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunik V, Peters B, Ofran Y. Structural consensus among antibodies defines the antigen binding site. PLoS Comput. Biol. 2012;8:e1002388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285572</ArticleId><ArticleId IdType="pubmed">22383868</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunik V, Ashkenazi S, Ofran Y. Paratome: an online tool for systematic identification of antigen-binding regions in antibodies based on sequence or structure. Nucleic Acids Res. 2012;40:W521–W524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3394289</ArticleId><ArticleId IdType="pubmed">22675071</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, et al. Cryo-EM structures reveal the molecular basis of receptor-initiated coxsackievirus uncoating. Cell Host Microbe. 2021;29:448–462.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8310385</ArticleId><ArticleId IdType="pubmed">33539764</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewat EA, Blaas D. Structure of a neutralizing antibody bound bivalently to human rhinovirus 2. EMBO J. 1996;15:1515–1523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC450059</ArticleId><ArticleId IdType="pubmed">8612574</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewat EA, Marlovits TC, Blaas D. Structure of a neutralizing antibody bound monovalently to human rhinovirus 2. J. Virol. 1998;72:4396–4402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC109670</ArticleId><ArticleId IdType="pubmed">9557730</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan G, Peters D, Racaniello VR. Poliovirus mutants resistant to neutralization with soluble cell receptors. Science. 1990;250:1596–1599.</Citation><ArticleIdList><ArticleId IdType="pubmed">2177226</ArticleId></ArticleIdList></Reference><Reference><Citation>Colston E, Racaniello VR. Soluble receptor-resistant poliovirus mutants identify surface and internal capsid residues that control interaction with the cell receptor. EMBO J. 1994;13:5855–5862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC395560</ArticleId><ArticleId IdType="pubmed">7813425</ArticleId></ArticleIdList></Reference><Reference><Citation>Shingler, K., Organtini, L. &amp; Hafenstein, S. Enterovirus 71 virus propagation and purification. BIO-Protoc. 4, e1117 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4991926</ArticleId><ArticleId IdType="pubmed">27547789</ArticleId></ArticleIdList></Reference><Reference><Citation>McDermott BM, Rux AH, Eisenberg RJ, Cohen GH, Racaniello VR. Two distinct binding affinities of poliovirus for its cellular receptor. J. Biol. Chem. 2000;275:23089–23096.</Citation><ArticleIdList><ArticleId IdType="pubmed">10770940</ArticleId></ArticleIdList></Reference><Reference><Citation>Punjani A, Rubinstein JL, Fleet DJ, Brubaker MA. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods. 2017;14:290-+.</Citation><ArticleIdList><ArticleId IdType="pubmed">28165473</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SHW. RELION: implementation of a bayesian approach to cryo-EM structure determination. J. Struct. Biol. 2012;180:519–530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690530</ArticleId><ArticleId IdType="pubmed">23000701</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. Sect. D.-Struct. Biol. 2004;60:2126–2132.</Citation><ArticleIdList><ArticleId IdType="pubmed">15572765</ArticleId></ArticleIdList></Reference><Reference><Citation>Croll TI. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. Sect. D.-Struct. Biol. 2018;74:519–530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6096486</ArticleId><ArticleId IdType="pubmed">29872003</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams PD, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. Sect. D.-Struct. Biol. 2010;66:213–221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815670</ArticleId><ArticleId IdType="pubmed">20124702</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen VB, et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. Sect. D.-Struct. Biol. 2010;66:12–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2803126</ArticleId><ArticleId IdType="pubmed">20057044</ArticleId></ArticleIdList></Reference><Reference><Citation>Smyth M, Pettitt T, Symonds A, Martin J. Identification of the pocket factors in a picornavirus. Arch. Virol. 2003;148:1225–1233.</Citation><ArticleIdList><ArticleId IdType="pubmed">12756627</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, et al. UCSF chimera-A visualization system for exploratory research and analysis. J. Comput. Chem. 2004;25:1605–1612.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 2021;30:70–82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737788</ArticleId><ArticleId IdType="pubmed">32881101</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao CA, Rossmann MG. Interpretation of electron density with stereographic roadmap projections. J. Struct. Biol. 2007;158:182–187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1978246</ArticleId><ArticleId IdType="pubmed">17116403</ArticleId></ArticleIdList></Reference><Reference><Citation>Sievers F, et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 2011;7:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3261699</ArticleId><ArticleId IdType="pubmed">21988835</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>